Top page > What's new
- 2010.06.17
- CanBas and Takeda to Terminate Collaboration for CBP501 for the Treatment of Cancer
- 2009.07.07
- Phase 2 for the clinical study of CBP501, an anticancer drug for non-small-cell lung carcinoma, has begun
(60.1KB) - 2009.04.03
- To increase the efficiency of drug screening methods, NEC's "ChemMiner(TM)" technology was introduced to the screen compounds in candidate pharmaceuticals
- 2009.10.16
- Phase 2 for the clinical study of CBP501, an anticancer drug for malignant pleural mesothelioma, has begun (51KB)
- 2008.06.01
- Report of the Phase 1 clinical study of CBP501 at ASCO2008
- 2008.05.01
- Phase 2 clinical study of the combined usage of CBP501, Pemetrexed and Cisplatin in patients with Malignant Pleural Mesothelioma initiated in the US
- 2007.04.02
- CanBas delivered the anticancer drug CBP501 to Takeda Pharmaceuticals. In the US, joint development and co-op promotion were started
- 2007.03.30
- CanBas and Takeda Pharmaceuticals to Sign a Joint Venture Agreement for Investigational Compounds for Treatment of Cancer
- 2007.01.01
- Paper on CBP501 published in Molecular Cancer Therapeutics
- 2006.11.01
- Midterm results of the CBP501 Phase 1 clinical study reported in the 18th EORTC-NCI-AACR
- 2006.10.01
- Phase 1 clinical study for CBP501 / Cisplatin combination therapy has been initiated in the US
- 2006.02.22
- Patent for the most advanced compound CBP501 issued by USPTO (34.7KB)
- 2006.02.16
- 2nd closing of 4th financing round, total procurement fund to JPY 2,500 million (36.4KB)
- 2005.12.29
- CanBas to procure JPY 2,360 million to invest in clinical studies of anticancer drugs
- 2005.11.01
- 4th financing round results in the appropriation of JPY 2,359 million for clinical study costs (37.1KB)
- 2005.07.01
- Journal of the National Cancer Institute Vol. 97, No. 14, 1026-1028, July 20, 2005 "New Checkpoint Blockers Begin Human Trials"
- 2005.05.01
- Phase 1 clinical study for CBP501 has been initiated in the US
